Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK “Delighted” By India’s Supreme Court Ruling In 10-Year Exclusive Marketing Rights Battle Over Avandia

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The Supreme Court of India has upheld a Calcutta High Court decision to grant exclusive marketing rights to GlaxoSmithKline's anti-diabetes drug Avandia in a landmark judgment that will have wide repercussions on product patent applications by multinational companies in India

You may also be interested in...



GSK India Managing Director Hasit Joshipura: An Interview With PharmAsia News (Part 2 of 2)

Joshipura discusses what lies ahead for India’s largest multinational drug company.

GSK India Managing Director Hasit Joshipura: An Interview With PharmAsia News (Part 2 of 2)

Joshipura discusses what lies ahead for India’s largest multinational drug company.

GSK India Managing Director Hasit Joshipura On What Lies Ahead For India’s Largest Multinational Drug Company: An Interview With PharmAsia News (Part 2 of 2)

GlaxoSmithKline India Managing Director Hasit Joshipura is known as one of the most aggressive multinational pharma directors in India in terms of expansion strategy. Some top GSK officials say he was brought in at the helm with the task of making GSK sharper in its marketing approach. Joshipura presented those capabilities in his earlier stint as the managing director at Johnson & Johnson India. Joshipura sat down with PharmAsia News' India bureau to discuss what lies ahead for India's largest multinational drug company.

UsernamePublicRestriction

Register

SC069541

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel